Advertisement

Drugs & Therapy Perspectives

, Volume 32, Issue 3, pp 91–97 | Cite as

Icosapent ethyl in hypertriglyceridaemia: a guide to its use

  • Katherine Lyseng-Williamson
  • Paul L. McCormack
  • Esther S. Kim
Adis Drug Q&A

Abstract

Icosapent ethyl (Vascepa®) is a high-purity ethyl ester of eicosapentaenoic acid (EPA), a long-chain omega-3 fatty acid associated with plasma triglyceride lowering. It does not contain the omega-3 fatty acid docosahexaenoic acid (DHA) that has been associated with increased low-density lipoprotein cholesterol (LDL-C) levels. Oral icosapent ethyl 2 g twice daily is approved in the USA for use as an adjunct to diet in lowering triglyceride levels in adult patients with severe hypertriglyceridaemia [triglyceride ≥500 mg/dL (≥5.65 mmol/L)]. In clinical trials in patients with very high or high triglyceride levels, icosapent ethyl 4 g/day significantly reduced triglyceride levels and other lipid parameters without increasing LDL-C levels, reduced levels of circulating markers of inflammation and was well tolerated. Case reports suggest that switching patients to icosapent ethyl from other omega-3 fatty acid products may improve lipid parameters.

Keywords

Triglyceride Level Ezetimibe Pitavastatin High Triglyceride Level Lower Triglyceride Level 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

The review was updated from the American Journal of Cardiovascular Drugs 2014;14(6):471–8 [48], and was reviewed by: H. E. Bays, Louisville Metabolic and Atherosclerosis Research Center, Louisville, KY, USA; J. C. Bradberry, Creighton University, Omaha, NE, USA; H. Ling, Hampton University, Hampton, VA, USA. During the peer review process, the manufacturer of icosapent ethyl was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Compliance with ethical standards

Funding

The preparation of this review was not supported by any external funding.

Conflicts of interest

K A. Lyseng-Williamson, P. McCormack and E. Kim are salaried employees of Adis/Springer, are responsible for the article content and declare no conflicts of interest.

References

  1. 1.
    Miller M, Stone NJ, Ballantyne C, et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2011;123(20):2292–333.CrossRefPubMedGoogle Scholar
  2. 2.
    Murad MH, Hazem A, Coto-Yglesias F, et al. The association of hypertriglyceridemia with cardiovascular events and pancreatitis: a systematic review and meta-analysis. BMC Endocr Disord. 2012;12(2).Google Scholar
  3. 3.
    Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. Lancet. 2014;384(9943):626–35.CrossRefPubMedGoogle Scholar
  4. 4.
    Ginsberg HN. The ACCORD (Action to Control Cardiovascular Risk in Diabetes) lipid trial: what we learn from subgroup analyses. Diabetes Care. 2011;34(Suppl 2):S107–8.PubMedCentralCrossRefPubMedGoogle Scholar
  5. 5.
    Saito Y, Yokoyama M, Origasa H, et al. Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis. 2008;200(1):135–40.CrossRefPubMedGoogle Scholar
  6. 6.
    Guyton JR, Slee AE, Anderson T, et al. Relationship of lipoproteins to cardiovascular events: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes). J Am Coll Cardiol. 2013;62(17):1580–4.CrossRefPubMedGoogle Scholar
  7. 7.
    The HPS2-THRIVE Collaborative Group. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371(3):203–12.Google Scholar
  8. 8.
    American Heart Association. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation. 2002;106(25):3143–421.Google Scholar
  9. 9.
    Berglund L, Brunzell JD, Goldberg AC, et al. Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012;97(9):2969–89.PubMedCentralCrossRefPubMedGoogle Scholar
  10. 10.
    Bradberry JC, Hilleman DE. Overview of omega-3 fatty acid therapies. PT. 2013;38(11):681–91.Google Scholar
  11. 11.
    Kones R, Rumana U. Current treatment of dyslipidemia: evolving roles of non-statin and newer drugs. Drugs. 2015;75(11):1201–28.CrossRefPubMedGoogle Scholar
  12. 12.
    Jacobson TA. Perspectives on a new prescription omega-3 fatty acid, icosapent ethyl, for hypertriglyceridemia. Clin Lipidol. 2014;9(2):149–61.CrossRefGoogle Scholar
  13. 13.
    Vascepa (icosapent ethyl) capsules: US prescribing information. Bedminster (NJ): Amarin Pharma Inc.; 2015.Google Scholar
  14. 14.
    Harris WS, Bulchandani D. Why do omega-3 fatty acids lower serum triglycerides? Curr Opin Lipidol. 2006;17(4):387–93.CrossRefPubMedGoogle Scholar
  15. 15.
    Rustan AC, Nossen JØ, Christiansen EN, et al. Eicosapentaenoic acid reduces hepatic synthesis and secretion of triacylglycerol by decreasing the activity of acyl-coenzyme A:1,2-diacylglycerol acyltransferase. J Lipid Res. 1988;29(11):1417–26.PubMedGoogle Scholar
  16. 16.
    Mason RP, Jacob RF. Eicosapentaenoic acid inhibits glucose-induced membrane cholesterol crystalline domain formation through a potent antioxidant mechanism. Biochim Biophys Acta. 2015;1848:502–9.CrossRefPubMedGoogle Scholar
  17. 17.
    Borow KM, Nelson JR, Mason RP. Biologic plausibility, cellular effects, and molecular mechanisms of eicosapentaenoic acid (EPA) in atherosclerosis. Atherosclerosis. 2015;242(1):357–66.CrossRefPubMedGoogle Scholar
  18. 18.
    Ishida T, Ohta M, Nakakuki M, et al. Distinct regulation of plasma LDL cholesterol by eicosapentaenoic acid and docosahexaenoic acid in high fat diet-fed hamsters: participation of cholesterol ester transfer protein and LDL receptor. Prost Leukot Essent Fatty Acids. 2013;88(4):281–8.CrossRefGoogle Scholar
  19. 19.
    Braeckman RA, Stirtan WG, Soni PN. Pharmacokinetics of eicosapentaenoic acid in plasma and red blood cells after multiple oral dosing with icosapent ethyl in healthy subjects. Clin Pharmacol Drug Devel. 2014;3(2):101–8.CrossRefGoogle Scholar
  20. 20.
    Stirtan WG, Braeckman RA, Bays HE, et al. Pharmacokinetic and triglyceride-lowering pharmacodynamic effects of icosapent ethyl (eicosapentaenoic acid ethyl ester) across clinical studies [abstract no. 173]. J Clin Lipidol. 2015;9(3):464.CrossRefGoogle Scholar
  21. 21.
    Weintraub HS. Overview of prescription omega-3 fatty acid products for hypertriglyceridemia. Postgrad Med. 2014;126(7):7–18.CrossRefPubMedGoogle Scholar
  22. 22.
    Braeckman RA, Stirtan WG, Soni PN. Phase 1 study of the effect of icosapent ethyl on warfarin pharmacokinetic and anticoagulation parameters. Clin Drug Invest. 2014;34(7):449–56.CrossRefGoogle Scholar
  23. 23.
    Braeckman RA, Stirtan WG, Soni PN. Effects of icosapent ethyl (eicosapentaenoic acid ethyl ester) on pharmacokinetic parameters of rosiglitazone in healthy subjects. Clin Pharmacol Drug Dev. 2015;4:143–8.PubMedCentralCrossRefPubMedGoogle Scholar
  24. 24.
    Braeckman RA, Stirtan WG, Soni PN. Effect of concomitant icosapent ethyl (eicosapentaenoic acid ethyl ester) on the pharmacokinetics of atorvastatin. Clin Drug Investig. 2015;35(1):45–51.PubMedCentralCrossRefPubMedGoogle Scholar
  25. 25.
    Braeckman RA, Stirtan WG, Soni PN. Effect of icosapent ethyl (eicosapentaenoic acid ethyl ester) on omeprazole plasma pharmacokinetics in healthy adults. Drugs R D. 2014;14(3):159–64.PubMedCentralCrossRefPubMedGoogle Scholar
  26. 26.
    Bays HE, Ballantyne CM, Kastelein JJ, et al. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial). Am J Cardiol. 2011;108(5):682–90.CrossRefPubMedGoogle Scholar
  27. 27.
    Ballantyne CM, Bays HE, Kastelein JJ, et al. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study). Am J Cardiol. 2012;110(7):984–92.CrossRefPubMedGoogle Scholar
  28. 28.
    Bays HE, Ballantyne CM, Braeckman RA, et al. Icosapent ethyl (eicosapentaenoic acid ethyl ester): effects upon high-sensitivity C-reactive protein and lipid parameters in patients with metabolic syndrome. Metab Syndr Relat Disord. 2015;13(6):239–47.CrossRefPubMedGoogle Scholar
  29. 29.
    Brinton EA, Ballantyne CM, Bays HE, et al. Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200–500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR study. Cardiovasc Diabetol. 2013;12:100.PubMedCentralCrossRefPubMedGoogle Scholar
  30. 30.
    Bays HE, Braeckman RA, Ballantyne CM, et al. Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on lipoprotein particle concentration and size in patients with very high triglyceride levels (the MARINE study). J Clin Lipidol. 2012;6(6):565–72.CrossRefPubMedGoogle Scholar
  31. 31.
    Ballantyne CM, Braeckman RA, Bays HE, et al. Effects of icosapent ethyl on lipoprotein particle concentration and size in statin-treated patients with persistent high triglycerides (the ANCHOR study). J Clin Lipidol. 2015;9(3):377–83.CrossRefPubMedGoogle Scholar
  32. 32.
    Ballantyne CM, Bays HE, Braeckman RA, et al. Icosapent ethyl (eicosapentaenoic acid ethyl ester): effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies [abstract no. 172]. J Clin Lipidol. 2015;9(3):463–4.CrossRefGoogle Scholar
  33. 33.
    Braeckman RA, Manku MS, Bays HE, et al. Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on plasma and red blood cell fatty acids in patients with very high triglyceride levels (results from the MARINE study). Prost Leukot Essent Fatty Acids. 2013;89(4):195–201.CrossRefGoogle Scholar
  34. 34.
    Ballantyne CM, Bays HE, Braeckman RA, et al. Icosapent ethyl (eicosapentaenoic acid ethyl ester): effects on apolipoprotein C-III in patients from the MARINE and ANCHOR studies [abstract no. 122]. J Clin Lipidol. 2014;8(3):313–4.CrossRefGoogle Scholar
  35. 35.
    Juliano RA, Braeckman RA, Manku MS, et al. Effects of icosapent ethyl, a highly purified eicosapentaenoic acid ethyl ester, on the fatty acid profile in plasma and red blood cells in statin-treated patients with persistent high triglycerides (results from the ANCHOR study) [abstract plus poster]. In: The Kern Lipid Conference; 2015.Google Scholar
  36. 36.
    Bays HE, Ballantyne CM, Braeckman RA, et al. Icosapent ethyl, a pure ethyl ester of eicosapentaenoic acid: effects on circulating markers of inflammation from the MARINE and ANCHOR studies. Am J Cardiovasc Drugs. 2013;13(1):37–46.PubMedCentralCrossRefPubMedGoogle Scholar
  37. 37.
    Castaldo RS. A retrospective case series of the lipid effects of switching from omega-3 fatty acid ethyl esters to icosapent ethyl in hyperlipidemic patients. Postgrad Med. 2014;126(3):268–73.CrossRefPubMedGoogle Scholar
  38. 38.
    Kedia AW, Lynch E. Effects of switching from omega-3-acid ethyl esters to icosapent ethyl in a statin-treated patient with elevated triglycerides. Postgrad Med. 2015;127(8):869–73.CrossRefPubMedGoogle Scholar
  39. 39.
    Hassan A, Tajuddin N, Shaikh A. Retrospective case series of patients with diabetes or prediabetes who were switched from omega-3-acid ethyl esters to icosapent ethyl. Cardiol Ther. 2015;4(1):83–93.PubMedCentralCrossRefPubMedGoogle Scholar
  40. 40.
    Crandell J, Tartaglia C, Tartaglia J. Retrospective case series of lipid effects in patients switched from EPA + DHA (omega-3-acid ethyl esters) to high-purity EPA (icosapent ethyl) [abstract no. 124]. Clin Cardiol. 2015;38(Suppl 1):12.Google Scholar
  41. 41.
    Hilleman DE, Malesker MA. Potential benefits of icosapent ethyl on the lipid profile: case studies. Clin Med Insights Cardiol. 2014;8:13–5.PubMedCentralCrossRefPubMedGoogle Scholar
  42. 42.
    Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet. 2007;369(9567):1090–8.CrossRefPubMedGoogle Scholar
  43. 43.
    Watanabe T, Miyamoto T, Miyasita T, et al. Combination therapy of eicosapentaenoic acid and pitavastatin for coronary plaque regression evaluated by integrated backscatter intravascular ultrasonography (CHERRY study): rationale and design. J Cardiol. 2014;64(3):236–9.CrossRefPubMedGoogle Scholar
  44. 44.
    Ando K, Watanabe T, Daidoji H, et al. Combination therapy of eicosapentaenoic acid and pitavastatin for coronary plaque regression evaluated by integrated backscatter intravascular ultrasonography: a randomized controlled trial [abstract no. 12007]. Circulation. 2015;132(Suppl 3):A12007.Google Scholar
  45. 45.
    Niki T, Wakatsuki T, Yamaguchi K, et al. Effects of the addition of eicosapentaenoic acid to strong statin therapy on inflammatory cytokines and coronary plaque components assessed by integrated backscatter intravascular ultrasound. Circ J (Epub 2015 Dec 11).Google Scholar
  46. 46.
    Amarin Pharma Inc. A study of AMR101 to evaluate its ability to reduce cardiovascular events in high risk patients with hypertriglyceridemia and on statin. The primary objective is to evaluate the effect of 4 g/day AMR101 for preventing the occurrence of a first major cardiovascular event (REDUCE-IT) [ClinicalTrials.gov Identifier NCT01492361] US National Institutes of Health, ClinicalTrials.gov. 2013. http://clinicaltrials.gov/ct2/show/NCT01492361. Accessed 24 Nov 2015.
  47. 47.
    Amarin Corporation. Amarin reaffirms its mission to improve patient care with commitment to completing REDUCE-IT cardiovascular outcomes study [media release]. 16 Sep 2014. http://investor.amarincorp.com/releasedetail.cfm?ReleaseID=870953.
  48. 48.
    Kim ES, McCormack PL. Icosapent ethyl: a review of its use in severe hypertriglyceridemia. Am J Cardiovasc Drugs. 2014;14(6):471–8.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  • Katherine Lyseng-Williamson
    • 1
  • Paul L. McCormack
    • 1
  • Esther S. Kim
    • 1
  1. 1.SpringerAucklandNew Zealand

Personalised recommendations